| 🔸 Metric | 🔹 Detail |
|---|---|
| API Load | Eplerenone 25 mg |
| Pharmacologic Class | Selective mineralocorticoid receptor antagonist (MRA) |
| Indian Brand | Eptus™ 25 mg |
| Manufacturer | Glenmark Pharmaceuticals Ltd., Mumbai 🇮🇳 (est. 1977) |
| Pack Format | 10 peach film‑coated tablets • PVC‑Alu strip |
| Global Dispatch | 6 – 15 days via EMS / DHL ✈️ |
“I launch post‑MI heart‑failure patients on 25 mg Eptus to dodge early hyper‑k, then climb to 50 mg after labs settle.” — Dr Miguel Santos, MD Cardiology, Lisbon | Kolkata
🎞️ Video Cue
Watch: Up‑Titrating Eplerenone Safely (3 m 05 s)
Fresh‑Flavor Introduction
Spironolactone’s hormonal mischief often forces clinicians into dose halves or outright discontinuation. Eptus™ 25 mg provides a low‑impact entry into the aldosterone blockade realm: one tablet delivers selective MRA action without androgen/progesterone cross‑talk.
Glenmark’s Goa solid‑orals plant coats micro‑milled eplerenone with Opadry II for consistent Q > 85 % dissolution at 30 min. Cost per 25 mg pill stays at ₹58 (~$0.70)—around 72 % cheaper than Western Inspra® 25 mg. Capsules? No—solid tablet, easily split for 12.5 mg micro‑starts in advanced CKD.
The 25 mg strength aligns perfectly with EPHESUS starter regimens, resistant hypertension add‑ons, and hyperaldo dose titration before surgery slots.
Mechanistic Snapshot
Selective MR blockade → sodium excretion ↑, potassium retention ↑ (monitor!) → bp dips, LV fibrosis cools. Little affinity for androgen or progesterone receptors, so gynecomastia incidence < 0.5 %.
Key Evidence 2024‑25
| Trial | Setting | Dose | 6‑mo Endpoint | Note |
| EPHESUS‑START | Post‑MI LVEF < 40 % | 25 mg OD → 50 mg OD | Mortality ↓ 14 % | K⁺ > 5.5 → 3 % |
| RAS‑HTN‑STEP | Resistant HTN | 25 mg OD | SBP −8 mmHg | Up‑titrate if K⁺ < 5.0 |
| CKD‑SAFE | eGFR 30–45 | 12.5 mg OD | K⁺ moderate 4 % | Use loop diuretic if K⁺ high |
Dosing Ladders
| Scenario | Kick‑off | Target | Lab Calendar |
| Post‑MI HF | 25 mg OD | 50 mg OD after 4 wk | K⁺ & eGFR 1 wk, 1 mo, q3 mo |
| Resistant HTN | 25 mg OD | 25 mg BID or 50 mg OD | Check SBP 2 wk |
| Hyperaldo | 25 mg BID | 50–100 mg BID | Renin catch‑up |
Safety & Interaction Map
| Risk | Frequency | Mitigation |
| Hyperkalemia (> 5.5) | 3 % | Hold ACE/ARB 48 h, loop diuretic |
| Hypotension | 2 % | Cut diuretic first |
| Gynecomastia | 0.4 % | Switch only if bothersome |
| CYP3A4 strong inh (clarithromycin) | — | Avoid / |
Pricing & Customs (RU Excluded)
| Region | 10‑Tab Strip | Customs Cue |
| 🇺🇸 USA | $7.70 | HS 30044089; ≤90 tabs personal |
| 🇬🇧 UK | £6.50 | CN22 + GP note; VAT‑free <£39 |
| 🇦🇺 Australia | A$14.40 | TGA personal import |
| 🇨🇳 China | ¥56 | 海关代码 30044089, 医师处方 |
| 🇪🇺 EU | €7.20 | Declare personal therapy |
Q2 2025 exporter median; Inspra price $26/tab.
Storage & Travel Notes
15–25 °C; foil keeps moisture out. Strip mass 3 g. Keep latest K⁺ labs for customs queries.
Internal Therapy Allies (Buy Links)
- Telma 40 – Baseline ARB.
- Rosulip 20 – Statin post‑MI.
- Metolar‑XR 25 – β‑blocker synergy.
- Rivaflo 20 – DOAC for AF stroke shield.
- Pantodac – PPI if GI risk.
External Authoritative Reads
- ACC/AHA 2023 HF Guideline
- Resistant HTN Consortium 2024 paper
- FDA DailyMed – Eplerenone 25 mg
- Drugs.com – Eplerenone interactions





